Zacks Investment Research on MSN
Will GILD's strong HIV portfolio reap rewards in 2026?
Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy ...
A 650-acre undeveloped property near Emigrant Gap is being transformed into a park with camping, trails, fishing and more ...
Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to ...
We need to revert to a fiscal rule anchored on deficit reduction to provide clarity to the market and also create space to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback